

12 January 2018

To: Recipients of M60, 1st ed.

From: Jennifer K. Adams, MT(ASCP), MSHA
Vice President, Standards and Quality

Subject: Correction

This notification is to inform you of corrections made to CLSI document M60, *Performance Standards for Antifungal Susceptibility Testing of Yeasts*, 1st ed. The corrections are described below.

Table 5, Zone Diameter and Equivalent Minimal Inhibitory Concentration Breakpoints for Select Antifungal Agents Against *Candida* spp. After 24-Hour Incubation:

A susceptible dose-dependent (SDD) column appeared in the previous edition of this table and was unintentionally omitted in the revision. The SDD column has been added to the "Equivalent MIC Breakpoints and Interpretive Categories, µg/mL" column.

As a result, additional corrections have been made for consistency with Table 1, Minimal Inhibitory Concentration Breakpoints for *In Vitro* Broth Dilution Susceptibility Testing of *Candida* spp. and Select Antifungal Agents After 24-Hour Incubation.

The corrections are shown as highlighted and/or stricken text in the table below. Where applicable, breakpoints have been bolded for consistency with Table 1. (Boldface type indicates information that is new or modified since the previous edition.) Specific changes are:

- For voriconazole, the MIC breakpoints for *C. albicans*, *C. krusei*, and *C. parapsilosis* have been corrected.
- For fluconazole:
 - SDD MIC breakpoints have been added for *C. albicans*, *C. glabrata*, *C. parapsilosis*, and *C. tropicalis*.
 - Resistant MIC breakpoints have been corrected for *C. parapsilosis* and *C. tropicalis*.

Table 5. Zone Diameter and Equivalent Minimal Inhibitory Concentration Breakpoints for Select Antifungal Agents Against *Candida* spp. After 24-Hour Incubation

Antifungal Agent	Species	Zone Diameter Breakpoints and Interpretive Categories, mm*				Equivalent MIC Breakpoints and Interpretive Categories, µg/mL			
		S	I	SDD	R	S	I	SDD	R
Caspofungin	<i>C. albicans</i>	≥17	15–16	–	≤14	≤0.25	0.5	–	≥1
	<i>C. glabrata</i>	–	–	–	–	≤0.12	0.25	–	≥0.5
	<i>C. guilliermondii</i>	≥13	11–12	–	≤10	≤2	4	–	≥8
	<i>C. krusei</i>	≥17	15–16	–	≤14	≤0.25	0.5	–	>1
	<i>C. parapsilosis</i>	≥13	11–12	–	≤10	≤2	4	–	≥8
	<i>C. tropicalis</i>	≥17	15–16	–	≤14	≤0.25	0.5	–	>1
Micafungin	<i>C. albicans</i>	≥22	20–21	–	≤19	≤0.25	0.5	–	≥1
	<i>C. glabrata</i> [†]	≥30	28–29	–	≤27	≤0.06	0.12	–	≥0.25
	<i>C. guilliermondii</i>	≥16	14–15	–	≤13	≤2	4	–	≥8
	<i>C. krusei</i>	≥22	20–21	–	≤19	≤0.25	0.5	–	≥1
	<i>C. parapsilosis</i>	≥16	14–15	–	≤13	≤2	4	–	≥8
	<i>C. tropicalis</i>	≥22	20–21	–	≤19	≤0.25	0.5	–	≥1
Voriconazole [‡]	<i>C. albicans</i>	≥17	15–16	–	≤14	≤0.5 ≤0.12	1 0.25–0.5	–	≥1 ≥1
	<i>C. glabrata</i> [§]	–	–	–	–	–	–	–	–
	<i>C. krusei</i>	≥15	13–14	–	≤12	≤0.12 ≤0.5	0.25–0.5 1	–	≥1 ≥2
	<i>C. parapsilosis</i>	≥17	15–16	–	≤14	≤0.5 ≤0.12	1 0.25–0.5	–	≥2 ≥1
	<i>C. tropicalis</i>	≥17	15–16	–	≤14	≤0.12	0.25–0.5	–	≥1
Fluconazole	<i>C. albicans</i>	≥17	–	14–16	≤13	≤2	–	4	4 8
	<i>C. glabrata</i>	–	–	≥15	≤14	–	–	≤32	32 64
	<i>C. krusei</i> [¶]	–	–	–	–	–	–	–	–
	<i>C. parapsilosis</i>	≥17	–	14–16	≤13	≤2	–	4	4 8
	<i>C. tropicalis</i>	≥17	–	14–16	≤13	≤2	–	4	4 8

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI and regret any inconvenience.